APVO
$4.63
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using A...
Recent News
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Wall Street Set to Open Higher Thursday; Jobless Claims Fall as Manufacturing Index Rebounds
US stocks look set to open higher Thursday following a lower-than-expected jobless claims report and
Aptevo Meets Nasdaq $2.5M Equity Requirement
Aptevo Therapeutics Inc. (NASDAQ:APVO) is among the best get rich quick stocks to buy now. As per the announcement last Tuesday, Aptevo Therapeutics Inc. (NASDAQ:APVO) has regained compliance with the Nasdaq Listing Rule 5550(b)(1), which requires listed companies to sustain at least $2.5 million in stockholders’ equity. The company received a green signal from the […]
Aptevo announces addition of preclinical candidate APVO455 to portfolio
Aptevo Therapeutics (APVO) announced the addition of preclinical candidate APVO455 to its growing portfolio of CD3-directed candidates built on the CRIS-7 derived CD3 binding domain-an approach demonstrating compelling potential across both hematologic and solid tumors. With this announcement, Aptevo now has a suite of three CD3-engaging molecules in development. All three share the same CRIS-7 derived binding domain with a low cytokine release profile. In addition, APVO455 and APVO442 contain C